SEC Form 4 · accession 0001615774-17-004693
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robin L Smith
Director
Period of report
Aug 21, 2017
Accepted (ET)
Aug 23, 2017 · 3:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $4.33 | Aug 21, 2017 | A | 75,000 | A | — | Jul 14, 2027 | Common Stock | 75,000 | 75,000 | D |
| Employee Stock Option (right to buy)F3 | $4.16 | Aug 21, 2017 | A | 50,000 | A | Dec 1, 2018 | Aug 21, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The award ("Option Grant 1") was granted, and approved by the board of directors of MYnd Analytics, Inc. (the "Registrant"), subject to stockholder approval of amendments to the Registrant's Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan"), pursuant to that certain Chairman Services Agreement (the "Agreement"), dated July 14, 2017 (the "Effective Date"), by and between the reporting person and the Registrant. The Registrant's stockholders approved the amendments to the Plan on August 21, 2017.
- F2Option Grant 1 vests in three equal installments as follows: 1/3 on the Effective Date, 1/3 on the six-month anniversary of the Effective Date and 1/3 on the twelve-month anniversary of the Effective Date.
- F3The award ("Option Grant 2") was granted, and approved by the board of directors of the Registrant, subject to stockholder approval of an amendment to a provision of the Registrant's Plan, pursuant to the Agreement. The Registrant's stockholders approved the amendment to the provision of the Plan on August 21, 2017.